Nov 6 2014

Americord Funds Trial: Beta Thalassemia Major

Posted by admin

Americord Funds Clinical Trial Investigating Umbilical Cord Blood Transplantation in Patients with Beta Thalassemia Major

Funds Will Support Research Into Safety and Efficacy of Umbilical Cord Stem Cell Transplantations to treat Beta Thalassemia Major

New York – November 6, 2014Americord Registry announced today that it has provided funding to Nanfang Hospital of Southern Medical University in Guangzhou, Guangdong, China. Funding will support research into the safety and efficacy of umbilical cord stem cell transplantations to treat Beta Thalassemia Major. Specifically, in this trial umbilical cord blood is used to reduce the occurrence of Graft-Versus-Host Disease in patients receiving haploidentical HSCT transplants to treat Beta Thalassemia Major.

Beta Thalassemia Major is a genetic blood disorder that involves the decreased production of normal adult hemoglobin. The condition results in a severe anemia that begins a few months after birth.

Americord’s donation of funds is part of the company’s corporate giving program, which was established to support research focused on the therapeutic uses of stem cells from umbilical cord blood, cord tissue, and placenta tissue.

“Americord is committed to supporting the advancement of stem cell technologies,” said Americord CEO Martin Smithmyer. “Our support of Dr. Chunfu Li’s trial at Nanfang Hospital is a manifestation of that desire.”

The study at Nanfang Hospital began in April 2014 and is anticipated to be complete by June 2015. It is registered with in accordance with best practices and requirements of the U.S. Food and Drug Administration.

For more information about the clinical trial:

< Back to Blog
Category: Press